Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients

被引：0
|
作者：
Cao, Lei [1 ]
Cao, Zhili [1 ]
Liu, Hongsheng [1 ]
Liang, Naixin [1 ]
Bing, Zhongxing [1 ]
Tian, Caijuan [2 ]
Li, Shanqing [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing 100730, Peoples R China
[2] Tianjin Marvelbio Technol Co Ltd, Tianjin Marvel Med Lab, Tianjin 300381, Peoples R China
来源：
CURRENT ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
non-small-cell lung cancer; immunotherapy; tumor mutation burden; microsatellite instability; programmed cell death protein-1; gene mutation; IMMUNE CHECKPOINT INHIBITORS; REDUCED FOLATE CARRIER; MICROSATELLITE INSTABILITY; SIGNALING PATHWAY; T-CELL; PD-L1; NSCLC; POLYMORPHISMS; RESISTANCE; THERAPIES;
D O I：
10.3390/curroncol29080451
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Microsatellite instability (MSI), high tumor mutation burden (TMB-H) and programmed cell death 1 ligand 1 (PD-L1) expression are hot biomarkers related to the improvement of immunotherapy response. Two cohorts of non-small-cell lung cancer (NSCLC) were collected and sequenced via targeted next-generation sequencing. Drug analysis was then performed on the shared genes using three different databases: Drugbank, DEPO and DRUGSURV. A total of 27 common genes were mutated in at least two groups of TMB-H-, MSI- and PD-L1-positive groups. AKT1, SMAD4, SCRIB and AXIN2 were severally involved in PI3K-activated, transforming growth factor beta (TGF-beta)-activated, Hippo-repressed and Wnt-repressed pathways. This study provides an understanding of the mutated genes related to the immunotherapy biomarkers of NSCLC.
引用
收藏
页码：5715 / 5730
页数：16
相关论文
共 50 条
  • [1] Potential biomarkers for immunotherapy in non-small-cell lung cancer
    Wang, Xing
    Qiao, Ziyun
    Aramini, Beatrice
    Lin, Dong
    Li, Xiaolong
    Fan, Jiang
    CANCER AND METASTASIS REVIEWS, 2023, 42 (03) : 661 - 675
  • [2] Potential biomarkers for immunotherapy in non-small-cell lung cancer
    Xing Wang
    Ziyun Qiao
    Beatrice Aramini
    Dong Lin
    Xiaolong Li
    Jiang Fan
    Cancer and Metastasis Reviews, 2023, 42 : 661 - 675
  • [3] Immunotherapy in frail non-small-cell lung cancer patients
    Gijtenbeek, Rolof G. P.
    Noordhof, Anneloes L.
    Asmara, Oke D.
    Groen, Harry J. M.
    van Geffen, Wouter H.
    LANCET, 2024, 403 (10440): : 1986 - 1986
  • [4] Immunotherapy rechallenge in patients with non-small-cell lung cancer
    Espana, S.
    Guasch, I.
    Carcereny, E.
    PULMONOLOGY, 2020, 26 (04): : 252 - 254
  • [5] Immunotherapy of non-small-cell lung cancer
    Reinmuth, Niels
    Merk, Martina
    Duell, Thomas
    ONKOLOGE, 2021, 27 (02): : 179 - 190
  • [6] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [7] Potential role of immunotherapy in advanced non-small-cell lung cancer
    de Mello, Ramon Andrade
    Veloso, Ana Flavia
    Catarina, Paulo Esrom
    Nadine, Sara
    Antoniou, Georgios
    ONCOTARGETS AND THERAPY, 2017, 10 : 21 - 30
  • [8] Plasma microRNAs as potential biomarkers for non-small-cell lung cancer
    Shen, Jun
    Todd, Nevins W.
    Zhang, Howard
    Yu, Lei
    Lingxiao, Xing
    Mei, Yuping
    Guarnera, Maria
    Liao, Jipei
    Chou, Amy
    Lu, Changwan Larry
    Jiang, Zhengran
    Fang, HongBin
    Katz, Ruth L.
    Jiang, Feng
    LABORATORY INVESTIGATION, 2011, 91 (04) : 579 - 587
  • [9] Identifying successful biomarkers for patients with non-small-cell lung cancer
    Friedlaender, Alex
    Bauml, Joshua
    Banna, Giuseppe Luigi
    Addeo, Alfredo
    LUNG CANCER MANAGEMENT, 2019, 8 (03)
  • [10] Non-Small-Cell Lung Cancer Role of the Immune System and Potential for Immunotherapy
    Carbone, David P.
    Gandara, David R.
    Antonia, Scott J.
    Zielinski, Christoph
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (07) : 974 - 984
12345